Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.
dc.contributor.author | Li, K | |
dc.contributor.author | Djoukhadar, I | |
dc.contributor.author | Zhu, X | |
dc.contributor.author | Zhao, S | |
dc.contributor.author | Lloyd, S | |
dc.contributor.author | McCabe, M | |
dc.contributor.author | McBain, Catherine A | |
dc.contributor.author | Evans, D | |
dc.contributor.author | Jackson, A | |
dc.date.accessioned | 2015-09-24T09:09:16Z | en |
dc.date.available | 2015-09-24T09:09:16Z | en |
dc.date.issued | 2015-08-26 | en |
dc.identifier.citation | Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. 2015: Neuro-oncology | en |
dc.identifier.issn | 1523-5866 | en |
dc.identifier.pmid | 26311690 | en |
dc.identifier.doi | 10.1093/neuonc/nov168 | en |
dc.identifier.uri | http://hdl.handle.net/10541/578677 | en |
dc.description.abstract | Antiangiogenic therapy of vestibular schwannoma (VS) in type 2 neurofibromatosis can produce tumor shrinkage with response rates of 40%-60%. This study examines the predictive value of parameter-derived MRI in this setting. | |
dc.language | ENG | en |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Neuro-oncology | en |
dc.title | Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. | en |
dc.type | Article | en |
dc.contributor.department | Wolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK | en |
dc.identifier.journal | Neuro-oncology | en |
html.description.abstract | Antiangiogenic therapy of vestibular schwannoma (VS) in type 2 neurofibromatosis can produce tumor shrinkage with response rates of 40%-60%. This study examines the predictive value of parameter-derived MRI in this setting. |